Satellos Bioscience: Q1 Earnings Snapshot
On a per-share basis, the Toronto-based company said it had a loss of 4 cents.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MSCLF at https://www.zacks.com/ap/MSCLF
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
a minute ago
- Los Angeles Times
Lake Forest-based Staar Surgical to be Acquired in $1.5-Billion Transaction
Global eye care company Alcon announced the acquisition of Lake Forest-based Staar Surgical Co. in a transaction with a total equity value of approximately $1.5 billion. Under the terms of the agreement, Alcon will purchase all outstanding shares of Staar common stock for $28 per share in cash, which represents approximately a 59% premium to the company's 90-day volume-weighted average price and a 51% premium to the closing price of Staar common stock on August 4 when the deal was first announced. 'With the number of high myopes rising globally, the acquisition of Staar enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as Lasik,' said David Endicott, chief executive of Alcon, in a statement. 'This transaction will allow us to provide treatment options across the full spectrum of myopia from contact lenses to surgical interventions.' An estimated 50% of the world will be myopic by 2050, and today nearly 500 million people are considered high myopes. Staar manufactures a family of contact lenses for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. The transaction is not subject to a financing condition. Alcon intends to finance the transaction through the issuance of short- and long-term credit facilities. It is anticipated to close in approximately six to 12 months. The boards of directors of Alcon and Staar have each unanimously approved the transaction. Morgan Stanley & Co. LLC is serving as financial advisor to Alcon, and Gibson Dunn & Crutcher LLP is serving as legal advisor to Alcon. Citi is serving as financial advisor to Staar, and Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Staar. Information for this article was sourced from Staar Surgical Co.
Business Wire
a minute ago
- Business Wire
Align Technology Initiates Patent Infringement Ligitation Against Angelalign Technology
SAN JOSE, Calif. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the filing of patent infringement lawsuits against Angelalign Technology, Inc. ('Angel') (Hong Kong Stock Exchange: a Shanghai-based manufacturer of clear aligners. The lawsuits allege that Angel's products and associated software infringe Align patents, which encompass innovations such as multilayer aligner materials, cutting-edge treatment planning, and advanced aligner features. These legal actions have been initiated in the United States, Europe and China, jurisdictions where Align has made significant investments in innovation, aligner fabrication and treatment planning. Align seeks both injunctive relief and monetary damages through these intellectual property enforcement efforts. 'Align is a pioneer in orthodontics, investing over $300 million annually (and approximately $2 billion since 2001) in research and development. It's an unrivalled level of investment that shows clearly our unwavering commitment to our customers and their patients. Our vision and passion for helping doctors transform the orthodontic industry from analog to digital through sustained investments fuels the company's innovation and technological leadership and advances orthodontic care around the world,' said Julie Coletti, EVP, chief legal and regulatory officer. 'We welcome fair and innovative competition, but we will protect our own innovations when companies choose to infringe our years of hard work and investment instead of legitimately performing research and development of their own. The patents we are asserting represent important components of our broad intellectual property portfolio and reflect key innovations in clear aligner therapy.' Align's Cutting-Edge Global Operations As a global leader in digital orthodontics and restorative dentistry with over 20 million Invisalign® patients treated worldwide, Align continues to transform the orthodontic industry through its global operations, advanced manufacturing capabilities, and doctor-directed treatment planning. Align's operations span the Americas, EMEA, and APAC, with clinical treatment planning centers in Costa Rica, Poland, China (Chengdu), Spain, France, Germany, and Japan. The company's global aligner manufacturing operations includes world-class facilities in Juarez, Mexico; Wroclaw, Poland; and Ziyang, China, forming the backbone of the world's largest 3D printing network for dental aligners. Align's investments in global operations are designed to bring its facilities closer to doctor-customers and their patients. In Mexico, the Juarez facility serves as a strategic node in Align's global supply chain, enabling fast and cost-effective delivery of aligners to customers in the U.S., Canada, Latin America, and beyond. In China, the Chengdu treatment planning center and Ziyang manufacturing facility are central to Align's 'Solution for China' strategy, supporting the local economy and one of its fastest-growing markets by helping Chinese doctors provide millions of Chinese consumers access to high-quality orthodontic care. Wroclaw, Poland is the operations hub for Align's EMEA business, bringing operations and support closer to the more than 62,700 Invisalign-trained doctors in the region. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 286.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Epoch Times
2 minutes ago
- Epoch Times
Tennessee Valley Authority to Be First US Utility to Purchase Power From a Small Modular Reactor
The Tennessee Valley Authority (TVA) is the first electric utility in the United States to formally commit to buying power generated by a small modular nuclear reactor, as part of a collaborative pact with Google and Kairos Power unveiled on Aug. 18. Under the agreement, the California-based reactor manufacturer's Hermes 2 Plant in Oak Ridge, Tennessee, will deliver up to 50 megawatts of electricity—enough to power 35,000 homes—by 2030 to power Google data centers in Montgomery County, Tennessee, and Jackson County, Alabama.
